{
  "id": "571e172bbb137a4b0c000002",
  "type": "factoid",
  "question": "When was empagliflozin FDA approved?",
  "ideal_answer": "Empagliflozin was approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25712444"
  ],
  "snippets": [
    {
      "text": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014486",
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017277"
  ],
  "exact_answer": "2014"
}